ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT04159896 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA events.

Conditions

Castration Levels of Testosterone
Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Prostate Carcinoma Metastatic in the Bone
Stage IVB Prostate Cancer AJCC v8

Interventions

DRUG: Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981
BIOLOGICAL: Nivolumab

Sponsor

Barbara Ann Karmanos Cancer Institute

Collaborators

[object Object]